Wunderman wins AstraZeneca's Faslodex

Share this article:

Pharmaceuticals marketer AstraZeneca has tapped Wunderman New York to launch a consumer campaign for Faslodex, a later-stage breast cancer prescription drug for women.

The direct marketing agency competed with CommonHealth and Digitas' Medical Broadcasting Company agency for the account. Billings were not disclosed.

"This helps us broaden our portfolio with their oncology division," said Steve Zammarchi, president/CEO of Wunderman New York. "We have to create awareness for the product in the direct-to-consumer marketplace."

Wunderman New York currently handles the Arimidex and Casodex/Zoladex brands, which are part of AstraZeneca's oncology medications.

A print campaign for Faslodex will begin this summer. Call to action and theme have not yet been disclosed.

Share this article:
You must be a registered member of Direct Marketing News to post a comment.

Sign up to our newsletters

Follow us on Twitter @dmnews

Latest Jobs:

More in Agency

Are You Really Ready for Customer Experience?

Are You Really Ready for Customer Experience?

Marketers can talk a good game about customer centricity, but actions speak louder than words.

Essentials in Content Marketing: Think like a best-selling author

Essentials in Content Marketing: Think like a best-selling ...

Imagine if all the electronic content thrown your way daily was actually printed on paper. To stand out from those piles of worthless pixels, you must offer your audiences intriguing ...

The Mobile-Email Marriage

The Mobile-Email Marriage

Marketers who considered leaving email at the altar are finding renewed passion for the channel as an ever-increasing number of customers triage, read, and click-through email on their smartphones.